Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Phase 3 Completed 500 enrolled Nymox Corporation

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.

Timeline

Start: 2009-05
Primary completion: 2014-05
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FEXAPOTIDE	Protein / enzyme biologic	2.5 mg	Other

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Summary

Timeline

Drugs

Indications